story of the week
Amivantamab Plus Lazertinib for Previously Untreated EGFR-Mutated Advanced NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
N. Engl. J. Med 2024 Oct 24;391(16)1486-1498, BC Cho, S Lu, E Felip, AI Spira, N Girard, JS Lee, SH Lee, Y Ostapenko, P Danchaivijitr, B Liu, A Alip, E Korbenfeld, J Mourão Dias, B Besse, KH Lee, H Xiong, SH How, Y Cheng, GC Chang, H Yoshioka, JC Yang, M Thomas, D Nguyen, SI Ou, S Mukhedkar, K Prabhash, M D'Arcangelo, J Alatorre-Alexander, JC Vázquez Limón, S Alves, D Stroyakovskiy, M Peregudova, MAN Şendur, O Yazici, R Califano, V Gutiérrez Calderón, F de Marinis, A Passaro, SW Kim, SM Gadgeel, J Xie, T Sun, M Martinez, M Ennis, E Fennema, M Daksh, D Millington, I Leconte, R Iwasawa, P Lorenzini, M Baig, S Shah, JM Bauml, SM Shreeve, S Sethi, RE Knoblauch, H HayashiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.